All News
AURA-LV Trial - Voclosporin Effective in Lupus Nephritis
The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.
Read Article
The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read Article
Growing Tick Population Comes with Health Concerns
CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses.
Read Article
Scleroderma Expert Treatment Preferences
Frustration may be the word that best characterizes many scleroderma management plans - owing to a lack of trials, lack of agreement and lack of clear guidance on management.
Read Article
Chikungunya Virus Vaccine Developed
Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.
Read Article
CIRT Trial - Methotrexate Fails at Cardiovascular Prevention
Methotrexate has been shown to reduce cardiovascular (CV) deaths in rheumatoid arthritis (RA) patients. Given that inflammation underlies the pathogenesis of atherothrombosis, Dr. Paul Ridker and colleagues studied the value of low dose methotrexate (MTX) in preventing cardiovascular events.
Read Article
RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)
Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com. Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.
Read Article
Intensive Patient Education Does Not Improve Low Back Pain Care
JAMA reports on a randomized clinical trial of 202 adults with acute low back pain showing the addition of intensive patient education failed to improve pain outcomes.
Read Article
Should Immunoglobulins be Monitored with Rituximab Use?
Boston researchers have found that in a large cohort study of patients receiving rituximab (RTX), most were not being monitored for hypogammaglobulinemia, despite the observed significant increase in severe infections and increased mortality in RTX treated patients.
Read Article
Low Short-Term Risks of NSAIDs in High Risk Patients
JAMA has published a large Canadian claims-based study showing that nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease was not associated with a significant safety risk - but this only looked at short-term outcomes (7-3
Read Article
Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis
Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).
Read Article
Doubling Down on IL-17 In Psoriatic Arthritis
The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.
Read Article
Spotlight on Interstitial Lung Disease at ACR 2018
Here are a few important advances in our understanding of interstitial lung disease (ILD) from the ACR 2018 meeting last week.
Read Article
Treat-to-Target Strategy Cuts Mortality in Gout Patients
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
Read Article
RheumNow ACR Week in Review: ACR Wrap-Up (10.26.18)
This past week in Chicago gave us a plethora of new and eye-opening research, people, KOLs, exhibits, sessions, guidelines, posters and a never-ending supply of coffee served in small paper cups. ACR 2018 highlights for me included:
Read Article
ACR 2018 - Day 4 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
ACR 2018 Podcast - Day 3
Audio Highlights and Interviews from Day 3 at the ACR 2018 meeting LISTEN HERE
Read Article
ACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included:
The PEXIVAS Study – 2x2 Trial of Plasma Exchange and Reduced Steroids in ANCA-Associated Vasculitis (AAV) - Abstract #2788
Read Article
ACR 2018 Podcast - Day 2B
Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTE
Read Article
ACR 2018 - Day 2 Report
Monday was a packed day of sessions and studies. Here are our just a few of our highlights.
Read Article